NovoSeven was developed and marketed by Novo Nordisk to treat and prevent bleeding episodes in people with hemophilia. It has been approved for more than 15 years in the United States, and is a valuable treatment option for both adults and children. NovoSeven treats several different types of hemophilia, including congenital hemophilia with or without inhibitors, factor VII deficiency and acquired hemophilia.
How NovoSeven works
NovoSeven, a protein, controls bleeding in hemophiliacs by stimulating the body’s natural clotting mechanisms. It is very similar to human factor VIIa, which is crucial in the series of reactions that cause blood to clot (also called the coagulation cascade). When a blood vessel is injured, activated factor VIIa kicks off chain reactions that ultimately produce fibrin. A clot is formed when fibrin proteins stick together at the site of injury.
NovoSeven in clinical trials
The first clinical trials showing that NovoSeven is a safe and effective treatment for hemophilia took place in the late 1990s. Since then, many studies have confirmed its efficacy and safety at varying doses, in both adults and children, and for different applications, such as before and during surgery or as an option for long-term prevention of bleeding episodes.
Administered by injecting a solution into a vein, NovoSeven is stable at room temperature and portable, which means it can be accessed quickly in the event of a bleeding episode. It takes less time to infuse than other clotting agents and controls bleeds quickly.
Hemophilia News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.